TEM Tempus AI, Inc.
USHealthcareAs of 2026-07-10 16:00
Why TEM matters now
Tempus AI, Inc. (TEM) is a US stock in Healthcare. The latest InvestLog snapshot shows $58.23 with -5.32% on the session and $10.16B in market capitalization; recent performance reads 1-month +11.66% and YTD -13.90%.
The latest financial table shown here is Q1 2026, with revenue of $348.1M, net income of $-125.9M, and EPS of $-0.71. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -2.4%.
The latest indexable market news headline is "Tempus to Report Second Quarter 2026 Financial Results on July 30" from Business Wire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $72.00; recent insider activity includes Epstein David R filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
21.84
P/S
6.50
EV/EBITDA
-71.31
DCF Value
$-151.05
FCF Yield
-2.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
69.6%
Operating Margin
-18.1%
Net Margin
-22.2%
ROE
-70.2%
ROA
-14.2%
ROIC
-13.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $348.1M | $-125.9M | $-0.71 |
| Q4 2025 | $367.2M | $-54.2M | $-0.30 |
| FY 2025 | $1.27B | $-245.0M | $-1.41 |
| Q3 2025 | $334.2M | $-80.0M | $-0.46 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$73.83
Target (Median)
$72.00
Target Range
$59.00 - $100.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Country
US
Exchange
—
Beta
3.62
Tempus AI, Inc. functions as a pioneering health technology enterprise. It specializes in delivering advanced diagnostic services, including cutting-edge genomic sequencing, PCR analysis, molecular genotyping, and various other anatomical and molecular pathology assessments. These vital services are provided to a diverse clientele, including medical practitioners, pharmaceutical companies, biotechnology innovators, scientific researchers, and other collaborating entities. The company offers "Insights," a licensed repository of de-identified clinical, molecular, and imaging data, complemented by a comprehensive suite of analytical and cloud-based computing services, primarily aimed at pharmaceutical and biotechnology firms. Additionally, its "Trials" program facilitates clinical trial matching services specifically for pharmaceutical companies. Tempus AI also manages several other platforms: "Next"; "Algos," a collection of algorithm-driven tests focused on oncology; "Hub," a versatile desktop and mobile application for ordering, managing, and receiving test results for patients; and "Lens," a dedicated portal enabling researchers and scientists to discover, access, and analyze the extensive Tempus dataset. Further demonstrating its commitment to innovation, Tempus AI has formed strategic alliances with AstraZeneca and Pathos AI, Inc. for the co-development of oncological therapeutic initiatives. Established in 2015, the company was initially known as Tempus Labs, Inc. before officially rebranding to Tempus AI, Inc. in January 2023. Its operations are based out of Chicago, Illinois.